Janus kinase inhibitors (JAKi), a class of targeted synthetic disease-modifying antirheumatic drugs, have significantly impacted clinical practice in the treatment of various autoimmune and inflammatory diseases. By inhibiting the JAK-STAT signaling pathway, these agents modulate the immune response, offering substantial therapeutic benefits across multiple domains [1].
